MX2018012580A - Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia. - Google Patents

Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.

Info

Publication number
MX2018012580A
MX2018012580A MX2018012580A MX2018012580A MX2018012580A MX 2018012580 A MX2018012580 A MX 2018012580A MX 2018012580 A MX2018012580 A MX 2018012580A MX 2018012580 A MX2018012580 A MX 2018012580A MX 2018012580 A MX2018012580 A MX 2018012580A
Authority
MX
Mexico
Prior art keywords
ischemia
methods
diagnosis
kits
patients
Prior art date
Application number
MX2018012580A
Other languages
English (en)
Inventor
Badimon Maestro Lina
Cubedo Ràfols Judit
Padró Capmany Teresa
Original Assignee
Fundacio Inst De Recerca De Lhospital De La Santa Creu I Sant Pau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst De Recerca De Lhospital De La Santa Creu I Sant Pau filed Critical Fundacio Inst De Recerca De Lhospital De La Santa Creu I Sant Pau
Publication of MX2018012580A publication Critical patent/MX2018012580A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

La invención se refiere a métodos para el diagnóstico de isquemia o daño tisular isquémico, métodos para la predicción de la evolución de la isquemia en un paciente que ha padecido un suceso isquémico, para la determinación del pronóstico de un paciente que ha padecido un suceso isquémico y para la determinación del riesgo de que un paciente que padece enfermedad coronaria estable padezca un suceso isquémico recurrente basado en la detección de los niveles de Apo J glicosilada. La invención también se refiere a un método para la determinación de los niveles de Apo J glicosilada en una muestra.
MX2018012580A 2016-04-12 2017-04-12 Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia. MX2018012580A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382167.1A EP3232200A1 (en) 2016-04-12 2016-04-12 Methods and kits for the diagnosis and risk stratification of patients with ischemia
PCT/EP2017/058768 WO2017178521A1 (en) 2016-04-12 2017-04-12 Methods and kits for the diagnosis and risk stratification of patients with ischemia

Publications (1)

Publication Number Publication Date
MX2018012580A true MX2018012580A (es) 2019-02-25

Family

ID=56008566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012580A MX2018012580A (es) 2016-04-12 2017-04-12 Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.

Country Status (14)

Country Link
US (1) US11486884B2 (es)
EP (2) EP3232200A1 (es)
JP (1) JP7075894B2 (es)
KR (1) KR102344344B1 (es)
CN (1) CN109154620B (es)
AU (1) AU2017251355A1 (es)
BR (1) BR112018070971A2 (es)
CA (1) CA3020666A1 (es)
IL (1) IL262245B (es)
MA (1) MA44658A (es)
MX (1) MX2018012580A (es)
RU (1) RU2750035C2 (es)
SG (1) SG11201808820QA (es)
WO (1) WO2017178521A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202103124WA (en) * 2018-10-23 2021-04-29 Glycardial Diagnostics S L Antibodies specific for glycosylated apoj and uses thereof
EP3890830A2 (en) * 2018-12-05 2021-10-13 Glycardial Diagnostics, S.L. Methods and compositions for the prevention and/or treatment of ischemia and of ischemia/reperfusion injury
KR102158726B1 (ko) 2019-04-17 2020-09-22 한림대학교 산학협력단 Itpr3 유전자 업스트림의 유전자간 영역을 포함하는 지연성 허혈 진단용 dna 메틸화 마커 조성물
KR102281657B1 (ko) 2019-12-23 2021-07-26 한림대학교 산학협력단 지연성 허혈 진단을 위한 cdhr5 유전자 과메틸화 마커
KR102281644B1 (ko) 2019-12-23 2021-07-23 한림대학교 산학협력단 지연성 허혈 진단을 위한 insr 유전자 과메틸화 마커
KR102312534B1 (ko) 2019-12-31 2021-10-13 한림대학교 산학협력단 뇌척수액 유래 미토콘드리아 마커를 이용한 지연성 허혈 진단 방법
KR102318236B1 (ko) 2020-02-18 2021-10-26 한림대학교 산학협력단 혈중 코펩틴의 농도를 이용한 지연성 뇌허혈 진단 방법
KR102336507B1 (ko) 2020-02-21 2021-12-06 한림대학교 산학협력단 국소뇌산소포화도를 이용한 지연성 뇌허혈 진단 방법
KR102369155B1 (ko) 2020-07-07 2022-02-28 한림대학교 산학협력단 근적외선 분광분석법을 이용한 지연성 뇌허혈 진단 방법
KR102473350B1 (ko) 2020-09-11 2022-12-05 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 racgap1 유전자 과메틸화 마커
KR102473349B1 (ko) 2020-09-11 2022-12-05 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 kifap3 유전자 과메틸화 마커
KR102473348B1 (ko) 2020-09-11 2022-12-05 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 kif3a 유전자 과메틸화 마커
KR102496589B1 (ko) 2020-09-11 2023-02-03 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 vhl 유전자 과메틸화 마커
KR102477501B1 (ko) 2020-09-15 2022-12-14 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 alb 유전자 저메틸화 마커
KR102477500B1 (ko) 2020-09-15 2022-12-14 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 oprm1 유전자 과메틸화 마커
KR102477502B1 (ko) 2020-09-15 2022-12-14 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 il5 유전자 저메틸화 마커
KR102466956B1 (ko) 2020-11-05 2022-11-11 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 dapk1 바이오마커
KR102398534B1 (ko) 2020-11-05 2022-05-13 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 bnip3l 바이오마커
KR102398533B1 (ko) 2020-11-05 2022-05-13 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 뇌척수액 마이토파지 마커
KR102470789B1 (ko) 2020-11-05 2022-11-25 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 pink1 바이오마커
CN113462744B (zh) * 2021-05-24 2023-06-23 中国药科大学 N-乙酰葡萄糖胺作为标志物在制备诊断缺血性脑中风试剂中的应用
KR20230022141A (ko) 2021-08-06 2023-02-14 에이치앤비지노믹스 주식회사 지능형 오믹스 기반 개인별 맞춤형 복잡질환 발병 위험도 정보 제공 방법 및 장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
CA2301634A1 (en) * 1997-07-15 1999-01-28 Pradeep Ghosh Determining alcohol intake using sialic acid/apo j
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
EP1746902A4 (en) * 2004-05-05 2007-06-13 Univ Northeastern MULTILEKTIN AFFINICHROMATOGRAPHY AND USE THEREOF
WO2011007764A1 (ja) * 2009-07-14 2011-01-20 独立行政法人産業技術総合研究所 肝疾患病態指標糖鎖マーカー
ES2364169B1 (es) 2010-02-09 2012-07-10 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (Titular al 50%) Uso de las isoformas de apo j como biomarcadores de lesión tisular.
EP2400304A1 (en) * 2010-06-22 2011-12-28 Centro de Investigación Cooperativa En Biomateriales ( CIC biomaGUNE) Method for the characterization of intermolecular interactions
JP2012107932A (ja) 2010-11-16 2012-06-07 Mitsubishi Chemicals Corp Ｃｌｕｓｔｅｒｉｎ蛋白質による脳梗塞の検査方法
DK3289363T3 (da) 2015-04-30 2022-02-28 Idexx Lab Inc Specifik påvisning af clusterin isoformer
CN107957498A (zh) * 2016-10-18 2018-04-24 厦门德馨尚品医疗科技有限公司 一种含有载脂蛋白j的试剂盒及其在临床诊断中的应用

Also Published As

Publication number Publication date
CA3020666A1 (en) 2017-10-19
SG11201808820QA (en) 2018-11-29
IL262245A (en) 2018-11-29
AU2017251355A1 (en) 2018-11-08
US20190128900A1 (en) 2019-05-02
JP7075894B2 (ja) 2022-05-26
EP3232200A1 (en) 2017-10-18
IL262245B (en) 2021-03-25
KR20190008216A (ko) 2019-01-23
JP2019516966A (ja) 2019-06-20
RU2750035C2 (ru) 2021-06-21
EP3443353B1 (en) 2024-03-13
CN109154620A (zh) 2019-01-04
US11486884B2 (en) 2022-11-01
BR112018070971A2 (pt) 2019-01-29
MA44658A (fr) 2019-02-20
EP3443353A1 (en) 2019-02-20
CN109154620B (zh) 2022-03-08
KR102344344B1 (ko) 2021-12-28
WO2017178521A1 (en) 2017-10-19
RU2018139780A (ru) 2020-05-12
RU2018139780A3 (es) 2020-07-24

Similar Documents

Publication Publication Date Title
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
WO2018187496A8 (en) PLASMA PROTEIN PROFILING FOR THE EARLY PROGNOSIS OF LUNG CANCER
WO2014201516A3 (en) Biomarker identification
WO2019213282A8 (en) Biomarkers for evaluating car-t cells to predict clinical outcome
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
BR112014031365A2 (pt) métodos de detectar doenças ou condições
MX2018009304A (es) Metodos de diagnostico y pronostico para episodios y enfermedades cardiovasculares.
WO2014028884A3 (en) Cancer diagnostics using biomarkers
MX2021012347A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
MX368099B (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
WO2015092046A3 (en) Prostate cancer biomarkers
MX2019002918A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
NZ729773A (en) Biomarkers for disease progression in melanoma
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
MX2014002030A (es) Biomarcadores de carcinoma de celulas renales y usos de los mismos.
WO2017081618A9 (en) Biomarkers for prospective determination of risk for development of active tuberculosis
WO2016198833A3 (en) Methods for analysing a urine sample
SG10201806729VA (en) Novel assay to detect human periostin
WO2016012864A3 (en) Biomarkers for anderson-fabry disease
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
MX2019002932A (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto.